Introduction {#S0001}
============

Tuberculosis (TB) is a prevalent infectious disease that affects the broader population. This disease is caused by *Mycobacterium tuberculosis* (MTB). According to the World Health Organization's (WHO) Global Tuberculosis Report 2018, approximately 1.3 million deaths were caused by TB in human immunodeficiency virus (HIV)-negative people. In addition, about 250,000 deaths were caused by TB in HIV-positive people.[@CIT0001] TB was also reported to be the leading cause of death resulting from a sole infectious agent worldwide.[@CIT0002] The emergence of multidrug-resistant TB (MDR-TB)[@CIT0003] and extensively drug-resistant tuberculosis (XDR-TB)[@CIT0004] has made the battle against TB more difficult because most currently available therapeutic options are ineffective against these resistant strains.[@CIT0005] Furthermore, the appearance of totally drug-resistant (TDR) strains has heightened this challenge because these strains are unaffected by the currently available anti-TB agents.[@CIT0006] Thus, developing novel therapeutic agents that are capable of combating resistant strains of MTB is necessary. After decades of academic and pharmaceutical industry investigation, in December 2012, bedaquiline became one of the first novel anti-TB drugs to be approved by the United States Food and Drug Administration (US FDA) for the treatment of MDR-TB.[@CIT0007] Following this, delamanid was approved by the European Medicines Agency in 2013.[@CIT0008]

MTB thymidylate kinase (MTB-TMK) is involved in DNA synthesis and is an essential target in the discovery of anti-TB compounds. Thymidine monophosphate kinase (TMK) catalyzes the phosphorylation of thymidine monophosphate (dTMP) to thymidine diphosphate (dTDP) using adenosine triphosphate (ATP) as the source of the phosphoryl group. The action of TMK is essential for maintaining the required levels of thymidine triphosphate (dTTP), which is a DNA building block required for DNA replication. Thus, inhibiting this enzyme is fatal to *M. tuberculosis* cells by rendering them unable to replicate and survive. The position of this enzyme in the dTTP synthesis pathway is crucial: it lies at the intersection of the de novo and salvage pathways. Further, this enzyme is the last specific enzyme involved in the synthesis of dTTP.[@CIT0009] Another important property of the MTB-TMK enzyme that makes it attractive for developing therapeutic agents is that it only shares a 22% sequence identity with human TMK. This allows for the development of selective inhibitors that target MTB-TMK without affecting healthy human cells.[@CIT0010]

Although most MTB-TMK inhibitors are thymidine monophosphate analogues that contain a nucleoside core,[@CIT0011]--[@CIT0017] some thymine non-nucleoside derivatives have also been reported to be potent MTB-TMK inhibitors.[@CIT0018]--[@CIT0021] Two novel classes, 3-cyanopyridones and 1.6-naphthyridin-2-ones, were recently identified as MTB-TMK inhibitors via high-throughput screening and structural optimization to improve potency ([Figure 1](#F0001){ref-type="fig"}).[@CIT0022] These two scaffolds share a common substructure with thymidine, namely, the unsubstituted lactam functional group, which is important for the formation of hydrogen bonds with thymidylate kinase receptors. Figure 1The representative scaffold of *Mycobacterium tuberculosis* thymidylate kinase inhibitors.

The tetrahydropyrimidine (THP) pharmacophore is found in various heterocyclic structures, which are known for their various pharmacological actions since they serve as antiviral,[@CIT0023] anticancer,[@CIT0024] antihypertensive,[@CIT0025] calcium-channel-blocking,[@CIT0026] antitubercular,[@CIT0027],[@CIT0028] antimicrobial,[@CIT0029],[@CIT0030] anti--inflammatory,[@CIT0031],[@CIT0032] antidiabetic,[@CIT0033] and larvicidal and insecticide agents.[@CIT0034]--[@CIT0036] Herein, we report the anti-TB activity of THP derivatives against H37Rv and multidrug-resistant (MDR) strains of MTB. On the basis of our previous findings on the promising anti-TB activity of THP scaffolds[@CIT0027],[@CIT0028] on whole-cell anti-TB properties and in a continuous effort to identify novel heterocyclic scaffolds that demonstrate potential anti-TB activity,[@CIT0037]--[@CIT0040] we screened six 1,2,3,4-tetrahydropyrimidinone (**1a--d**) and 1,2,3,4-tetrahydropyrimidinethione (**2a--b**) analogues ([Scheme 1](#SCH0001)) for whole-cell anti-TB activity against H37Rv and MDR strains of MTB by the resazurin microplate assay (REMA) plate method.

Materials and Methods {#S0002}
=====================

Chemistry {#S0002-S2001}
---------

The chemicals reported here were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA), while the solvents were obtained from Millipore Sigma (Burlington, MA, USA). Thin-layer chromatography (TLC) using silica gel (Sigma-Aldrich Co.) on aluminum foil was employed to observe the chemical reactions; n-hexane and ethyl acetate (4:6) were used as the solvent. The reactions were visualized under an ultraviolet (UV)-light/iodine chamber. B-545 was used to measure the melting points (Büchi, Labortechnik, Flawil, Switzerland). Infrared (IR) spectra were recorded on a Nicolet 6700 Fourier-transform infrared (FT-IR) spectrometer. Further, ^1^H and ^13^C-NMR spectra were recorded using Bruker AVANCE III 600 MHz (Bruker Corporation, Billerica, MA, USA) with CDCl~3~ (solvent). Chemical shifts (δ) were indicated in ppm, with tetramethylsilane (TMS) as a reference; coupling constants (J) were recorded (Hz). The splitting pattern was documented as follows: s, singlet; d, doublet; q, quartet; and m, multiplet. Liquid chromatography/mass spectrometry (LC--MS; Agilent 1100 series) was used to measure the mass spectra in conjunction with MSD and 0.1% aqueous trifluoroacetic acid in an acetonitrile system on a C18-BDS column. Then, an elemental analysis was carried out using the analyzer FLASH EA 1112 CHN (Thermo Finnigan LLC, New York, NY, USA).

The test compounds 1,2,3,4-tetrahydropyrimidinone (**1a--c**) and 1,2,3,4-tetrahydropyrimidinethione (**2b**) ([Scheme 1](#SCH0001)) were synthesized using our previously reported procedures,[@CIT0041] and novel compounds **1d** and **2a** were synthesized by following a similar procedure. [Table 1](#T0001){ref-type="table"} details the physicochemical constants of the test compounds.Table 1Physicochemical Characteristics of Methyl 6-Methyl-2-Oxo-4-Substituedphenyl-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate (**1a--d**) and Methyl 6-Methyl-4-Substituedphenyl-2-Thioxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate (**2a--b**)EntryMol Formulae (Mol Mass)ArYield (%)^a^m.p (°C)cLogP^b^Synthetic ReferenceReportedFound1aC~14~H~13~F~3~N~2~O~3~ (314)4-CF~3~83188--190190--1912.9788\[[@CIT0042]\]1bC~13~H~13~FN~2~O~3~ (264)4-F79173--174174--1752.2388\[[@CIT0043]\]1cC~15~H~19~N~3~O~3~ (289)4-N(CH~3~)~2~84238--240239--2402.2608\[[@CIT0042]\]1dC~13~H~12~N~4~O~7~ (336)2,4-(NO~2~)~2~90--205--2061.5018Novel compound2aC~14~H~13~F~3~N~2~O~2~S (330)4-CF~3~86--216--2173.1084Novel compound2bC~13~H~13~FN~2~O~2~S (280)4-F89208--210209--2102.3684\[[@CIT0044],[@CIT0045]\][^1]

The Synthesis of Methyl 4-(2,4-Dinitrophenyl)-6-Methyl-2-Oxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate (1d) {#S0002-S2002}
------------------------------------------------------------------------------------------------------------

A mixture of 2.4-dinitrophenyl benzaldehyde (1.2 mmol), urea (1.2 mmol), and methyl acetoacetate (1.5 mmol) in methanol was added to a 50 mL round-bottomed flask and refluxed for 15 hrs using concentrated hydrochloric acid as a catalyst. The reaction was examined on a thin-layer chromatography plate. Once the reaction was achieved, the reaction medium was poured into ice-cold water with stirring. The obtained precipitate was filtered and washed with aqueous methanol and then dried. The resulting product was recrystallized using ethanol to obtain the pure compound. The remaining compounds were prepared using the aforementioned procedure; the physicochemical characteristics are tabulated in [Table 1](#T0001){ref-type="table"}.

Methyl 4-(2,4-Dinitrophenyl)-6-Methyl-2-Oxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate (1d) {#S0002-S2003}
-------------------------------------------------------------------------------------------

Appearance: brown amorphous compound; FT-IR (KBr) cm^--1^ = 3220, 3087, 1728, 1677, 1596, 1421. ^1^H-NMR (600 MHz CDCl~3~) *δ* = 9.54 (1H, bs), 8.65--8.64 (1H, d, J = 1.8 Hz), 8.53--8.52 (1H, m), 8.04 (1H, bs), 7.86--7.85 (1H, d, J = 7.2 Hz), 5.86 (1H, s), 3.39 (3H, s), 2.27 (3H, s); ^13^C-NMR (100 MHz CDCl~3~) *δ* = 165.41, 151.44, 150.89, 147.67, 147.04, 145.96, 131.52, 128.82, 119.93, 97.73, 51.36, 49.96, 18.40. LC--MS (ESI Positive): *m/z* = (M+H)^+^: 337. Anal. calculated for C1~3~H~12~N~4~O~7;~ C, 46.44, H, 3.60, N, 16.66; Found; C, 46.45, H, 3.65, N, 16.61.

The Synthesis of Methyl 6-Methyl-2-Thioxo-4-(4-(Trifluoromethyl)Phenyl)-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate (2a) {#S0002-S2004}
-----------------------------------------------------------------------------------------------------------------------

A mixture of thiourea (1.2 mmol), 4-trifluoromethyl benzaldehyde (1.2 mmol), and methyl acetoacetate (1.5 mmol) in methanol was added to a 50 mL round-bottomed flask and refluxed for 15 hrs using concentrated hydrochloric acid as a catalyst. The reaction was examined on a thin-layer chromatography plate. Once the reaction was achieved, the cooled reaction medium was poured into ice-cold water with constant stirring. The obtained precipitate was filtered and washed with aqueous methanol and then dried over sodium sulfate. The resulting product was recrystallized using ethanol to obtain the pure compound. The remaining compound **2b** was prepared using the aforementioned procedure; the physicochemical characteristics are tabulated in [Table 1](#T0001){ref-type="table"}.

Methyl 6-Methyl-2-Thioxo-4-(4-(Trifluoromethyl)Phenyl)-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate (2a) {#S0002-S2005}
------------------------------------------------------------------------------------------------------

Appearance: yellow amorphous powder; FT-IR (KBr) cm^--1^ = 3390, 3124, 1716, 1666, 1517, 1456, 1236. ^1^H-NMR (600 MHz CDCl~3~) *δ* = 8.01 (1H, bs), 7.62--7.59 (2H, m), 7.51 (1H, bs), 7.44--7.43 (2H, m), 5.48 (1H, s), 3.68 (3H, s), 2.39 (3H, s); ^13^C-NMR (150 MHz CDCl~3~) *δ* = 175.8, 165.46, 145.9, 143.45, 129.05, 127.07, 126.00, 125.98, 125.79, 101.2, 55.60, 51.6, 18.58; LC--MS (ESI Positive): *m/z* = (M+H)^+^: 331. Anal. calculated for C~14~H~13~F~3~N~2~O~2~S; C, 50.91, H, 3.97, N, 8.48; Found; C, 50.95, H, 3.95, N, 8.49.

Anti-Tubercular Activity {#S0002-S2006}
------------------------

### Resazurin Microplate Assay (REMA) {#S0002-S2006-S3001}

Anti-TB screening of test compounds **1a--d** and **2a--b** was carried out against H37Rv and MDR strains of *Mycobacterium tuberculosis* via the REMA plate method, as described in our previous communication.[@CIT0028],[@CIT0046] Testing was conducted on stored MDR-MTB cultures isolated from patient sputum specimens; pure colonies from a single strain were retrieved from storage and subcultured for further testing. Clinical isolates of a well-characterized MDR strain of *Mycobacterium tuberculosis* with resistance to rifampicin (Rif) and isoniazid (Inh) were selected for testing. Mutations within the *rpoB* gene and *katG* or *inhA* genes conferred resistance to Rif and Inh, respectively.

### Determining the Minimum Inhibitory Concentration (MIC) {#S0002-S2006-S3002}

All six test compounds **1a--d** and **2a--b** were assessed using the agar incorporation method, which was performed three times against the H37Rv strain and the MDR-TB strain, which demonstrates resistance to rifampicin (1 µg/mL) and isoniazid (0.2 µg/mL). MIC was determined.[@CIT0047] The MTB reference strain H37Rv (American Type Culture Collection \[ATCC\]: 25177), as well as MDR-TB were cultured for a total of 3 weeks in Middlebrook 7H11 medium,[@CIT0048] and were then supplemented with OADC (0.005%, v/v, oleic acid; 0.2%, w/v, glucose; 0.085%, w/v, NaCl; 0.02%, v/v, catalase; and 0.5%, 171 w/v, bovine serum albumin \[BSA\]). Incubation was set at 37°C. The obtained cultures were utilized to prepare an inoculum in a sterile tube with 0.05% Tween 80 and 4.5 mL of phosphate buffer with glass beads (5 mm in diameter) by vortexing. After this, the cultures settled for a total of 45 mins; the clear bacterial supernatant was standardized to McFarland Number 1 using sterile water. The resulting bacterial concentration was approximately 1×10^7^ CFU/mL, which was then diluted with sterile water. Overall, 100 µL of the dilution was added onto Middlebrook 7H10 agar plates containing 8--0.125 µg/mL of the agent. The drug (8 µg/mL) was dissolved in distilled water and diluted to the required concentration before being added to the agar medium. The drug MICs were read three weeks following 37°C incubation, which were regarded as the minimum drug concentration that could inhibit \>99% growth of the bacterial culture when compared to controls. The results of this evaluation are presented in [Table 2](#T0002){ref-type="table"}.Table 2The Anti-Tubercular Activity of Methyl 6-Methyl-2-Oxo-4-Substituedphenyl-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate (**1a--d**) and Methyl 6-Methyl-4-Substituedphenyl-2-Thioxo-1,2,3,4-Tetrahydropyrimidine-5-Carboxylate (**2a--b**) Analogues Against H37Rv and MDR-MTB Strains of *Mycobacterium tuberculosis*EntryMIC (µg/mL)H37Rv\*MDR-MTB\*\*1a16NA1bNANA1cNANA1dNANA2a321282b64NAIsoniazid2--[^2][^3]

Computational Chemistry {#S0002-S2007}
-----------------------

Accelry's Discovery Studio 4.0 was used for molecular modeling by following the reported docking protocol.[@CIT0049] The CHARMm force-fields algorithm was employed. In the docking study, the X-ray co-crystal structures of the ligand and enzyme (PDB code: 5NQ5) were used to evaluate the binding affinity of the new THP. In prior docking studies, the protein was retrieved from the Protein Data Bank (PDB) and was subjected to the following sequences: Ligands and water exclusion, protein preparation and minimization energy, and the concerned ligand into the minimized protein to select the cavity site responsible for the binding domain. Molecular docking was conducted using the CDocker protocol. Docking scores obtained from the 10 best conformations were recorded as CDocker energy and CDocker interaction energy. The scores were then ranked according to CDocker energy. Stronger negative CDocker scores indicate more favorable binding interactions. The highest negative scores for PLP1, PLP2, Jain, and PMF demonstrated the strongest binding affinities between receptors and ligands; this was used to refine the binding pose. The docking protocol was validated by re-docking the original ligand to the receptor to ensure the correct binding pose, as reported in X-ray co-crystal PDB 5NQ5. The root mean square deviation difference between the docked and the actual crystal bound conformation of the native ligand was found to be 0.175 Å ([[Figure S7](https://www.dovepress.com/get_supplementary_file.php?f=228381.doc)]{.ul}).

ADME Prediction {#S0002-S2008}
---------------

The SwissADME Web server[@CIT0050] was used to predict the pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), of all compounds. The Lipinski rule of five conditions, the number of rotatable bonds, and total polar surface area (TPSA) were calculated to gain insights into the oral bioavailability of the compounds since these factors are known to influence it.[@CIT0051],[@CIT0052] The probability of a compound being a substrate for p-glycoprotein (p-gp) was also calculated because this protein is responsible for the efflux of xenobiotics outside the cells, which serves as a drug-resistance mechanism.[@CIT0053],[@CIT0054] Blood--brain barrier (BBB) permeability was also predicted for all compounds to consider the possibility of the agent entering the central nervous system (CNS), which may be undesirable and would require structural modification of the compounds. Additionally, the potential inhibition of some important cytochrome P450 (CYP 450) isoforms (namely, CYP1A2, CYP2C9, and CYP2D6) was predicted to investigate possible drug--drug interactions that can result from inhibiting one or more of these CYP 450 isoforms.[@CIT0055]

Results and Discussion {#S0003}
======================

Rational Design {#S0003-S2001}
---------------

In the current investigation, the title compounds, incorporating a pyrimidine core, have been designed as potential MTB-TMK inhibitors ([Figure 2A](#F0002){ref-type="fig"}). MTB-TMK inhibitors must be able to form critical hydrophilic interactions with amino acid residues ASN 100, ARG 74, and ARG 95 to ensure binding. The docking pose of thymidine monophosphate in the active site, depicted in [Figure 2B](#F0002){ref-type="fig"}, reveals the carbonyl and NH group of the thymine core-forming hydrogen bonds with the amino-acid backbone comprising ASN 100 and ARG 74, respectively; an additional hydrogen bond is formed between the oxygen atom of phosphate and the residue ARG 95. Figure 2(**A**) Design of tetrahydro-pyrimidines as potential MTB-TMK inhibitors. (**B**) Superposition of thymidine monophosphate (yellow) and the molecular target pyrimidinone (violet) in the active site of MTB-TMK (PDB: 5NQ5).

When exploiting the general binding feature of the TMK receptor, the application of a fragment-based design reveals a 1,2,3,4-tetrahydropyrimidinone (THP)-based scaffold for potential MTB-TMK inhibitors. We sought to investigate the MTB activity of six substituted phenyl THP derivatives ([Scheme 1](#SCH0001)). THP was chosen as a molecular target for many reasons, including the structural similarities that it shares with MTB-TMK inhibitors, the variety of analogues that can be generated via a simple synthetic operation, and its excellent pharmacological and safety profile. The starting point of our study was to recognize that the unsubstituted lactam functional group present in the THP core would be essential for interacting with the thymidylate kinase receptor. Indeed, a preliminary docking study of the unsubstituted aryl THP into the binding site suggested that THP interacts favorably with the receptor by hydrogen bonding with the key residues ASN 100 and ARG 74 ([Figure 2B](#F0002){ref-type="fig"}). In addition, the aryl group of THP occupies the same pocket as the ribose moiety of thymidine monophosphate. The presence of an appropriate substituent on the phenyl ring would, therefore, be a determinant when generating a bioactive molecule. Therefore, we hypothesized that the target molecule might be an effective anti-TB agent.

Chemistry {#S0003-S2002}
---------

The synthetic routes used to construct test compounds 1,2,3,4-tetrahydropyrimidinones (**1a--d**) and 1,2,3,4-tetrahydropyrimidinethiones (**2a--b**) are depicted in [Scheme 1](#SCH0001). The compounds were synthesized by the Biginelli reaction, and the yields were found to be satisfactory. Scheme 1Synthetic route to pyrimidinones **1a--d** and pyrimidinethiones **2a, b**.

The test compounds were purified via recrystallization; the purity of the test compounds was ascertained by HPLC and determined to be \>99%. The identities of the reported compounds were confirmed by comparing their melting points and molecular masses from LC--MS with the reported and calculated values, respectively. Fourier-transform infrared (FT-IR) spectra of compounds **1d** ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=228381.doc)]{.ul}) and **2a** ([[Figure S4](https://www.dovepress.com/get_supplementary_file.php?f=228381.doc)]{.ul}) revealed carbonyl stretching of the ester functional group in the range of 1716--1728 cm^--1^. In proton nuclear magnetic resonance (NMR), the methyl group on 1,2,3,4-tetrahydropyrimidine and ester group were observed at δ 3.39--3.68 and δ 2.27--2.39, respectively ([[Figures S2](https://www.dovepress.com/get_supplementary_file.php?f=228381.doc)]{.ul} and [[S5](https://www.dovepress.com/get_supplementary_file.php?f=228381.doc)]{.ul}). In carbon-13 NMR, the carbonyl of the ester functional group appeared in the range of 165.41--175.8 ppm ([[Figures S3](https://www.dovepress.com/get_supplementary_file.php?f=228381.doc)]{.ul} and [[S6](https://www.dovepress.com/get_supplementary_file.php?f=228381.doc)]{.ul}). The molecular ion peaks in LC--MS corresponded with the proposed molecular weight. The elemental analysis results fell within ±0.4% of the obtained values, and the cLog*P* of the title compound was calculated with ChemDraw Professional 16 (range: 1.5018--3.1084).

Anti-Tubercular Activity {#S0003-S2003}
------------------------

Test compounds 1,2,3,4-tetrahydropyrimidinones **(1a--d)** and 1,2,3,4-tetrahydropyrimidinethiones **(2a--b)** were evaluated for their whole-cell anti-TB activity against the H37Rv and MDR strains of MTB. Well-characterized clinical isolates with resistance to rifampicin (Rif) and isoniazid (Inh) were selected for testing. Mutations within the *rpoB* gene and *katG* or *inhA* genes conferred resistance to Rif and Inh, respectively. MDR-MTB was found to be resistant to isoniazid and rifampicin at 0.2 and 1 µg/mL, respectively. The growth inhibition of the tested compounds was given in [Table 2](#T0002){ref-type="table"}. From our studies, compound **2a** demonstrated potential as a promising anti-TB agent against the H37Rv and MDR strains of MTB at 32 and 128 µg/mL respectively. Although compounds **1a** and **2b** demonstrated anti-TB activity against the H37Rv strain of MTB, they failed to exhibit activity against the MDR strain of MTB, which was resistant to the first-line antituberculosis drugs rifampicin and isoniazid. In addition, compound **1a**, substituted by a trifluoromethyl group at fourth position of the benzene ring, was the most potent compound in the series and found to be 8 times less active than the reference isoniazid drug. Compound **1a** was observed to exhibit two-fold higher activity than compound **2a**, demonstrating the importance of having carbonyl instead of thiocarbonyl in the pyrimidine ring. Lastly, compounds **1b, 1c**, and **1d** did not show any anti-TB activity up to a concentration of 128 µg/mL against both MTB strains. It is interesting to note that the type and the position of the substituent on the aromatic ring play an important factor to obtain a bioactive THP compound. The presence of the trifluoromethyl group at the fourth position was highly favorable to the MTB growth inhibition while replacing by N(CH~3~)~2~ substituent leads to the inactive compound. The molecule **1d** bearing two nitro groups at ortho and para position on the aryl ring was detrimental to the activity of the compounds. Replacement of the trifluoromethyl group by fluorine atom at the fourth position of the benzene ring reduces the potency of the compound. Molecular modeling investigation will provide insight into the structural requirement contributing to the potency of THP and may provide additionally an explanation for the inactivity of compounds **1b, 1c**, and **1d**.

Computational Chemistry {#S0003-S2004}
-----------------------

The thymidylate kinase receptor was chosen for this study on the basis of the results of our preliminary docking study conducted with unsubstituted 4-phenyltetrahydopyrimidinone ([Scheme 1](#SCH0001)). It is interesting to note that the lack of activity observed for compounds **1a** and **2a** against cross-drug resistance to first-line anti-TB drugs may provide evidence for their mechanism of action. Our compounds may potentially act as either RNA polymerase inhibitor (rifampicin molecular target) or InhA inhibitor (isoniazid molecular target). However, the computational study of our compounds against both receptors did not convincingly explain the inactivity of derivatives **1c** and **1d**, which demonstrated favorable docking interactions against rifampicin and isoniazid molecular receptors. This is the reason why our computational chemistry was conducted against the thymidylate kinase receptor. Another aspect of this computational study that should be addressed is that THP exists as R and S stereoisomers as a result of a stereogenic center at position 4 of the structure. According to the docking results reported in [Table 3](#T0003){ref-type="table"}, the stereoisomer (*R*) **1a** displayed the highest docking score with a CDocker energy interaction of −36.75 kcal/mol. The interaction pattern of (*R*) **1a** with the active site revealed four H-bonds with residues ASN 100, ARG 74, ARG 95, and ARG 107 ([Figure 3](#F0003){ref-type="fig"}). As expected, the THP ring interacted favorably through a hydrophilic interaction of ASN 100 and ARG 74 with carbonyl and NH, respectively. The trifluoromethyl group formed a moderate H-bond with the residue ARG 95, and a strong H-bond interaction was observed between the carbonyl ester and the amino acid ARG 107. These four key interactions may strongly contribute to the anti-mycobacterial activity of THP (*R*) **1a**. In addition, two π interactions were observed between the phenyl ring and TYR 103 (π--π) and ARG 95 (π--cation). However, the stereoisomer (*S*) **1a** displayed only two H-bond interactions between the THP ring and residues ARG 74 and ASN 100. The trifluoromethyl group pointed away from ARG 95, preventing any possible hydrophilic interaction. Further, stereoisomer (*S*) **1a** did not show any π interactions. We also noted that the docking score of the stereoisomer (*S*) **1a** is similar to that of (*R*) **1a**, most likely because of the stronger interaction observed between (*S*) **1a** and the residue ASN 100, with an H-bond distance of 2.61 Å, compared with 3.01 Å for (*R*) **1a**. In general, the activity of THP derivatives against mycobacteria was attributed to the R form. The loss of potency for compound **1b** and the weak potency for thiooxopyrimidines **2a** and **2b** can be explained by the type and strength of the interaction. Indeed, derivatives (*R*) **1a** and (*R*) **2a** and **2b** did not show H-bonding with ASN 100 or a π--π interaction with TYR 103. As for the inactivity of compounds **1c** and **1d**, it could be attributed to their binding modes, which differ from those of the active compounds **1a, 2a**, and **2b**. Indeed, the binding modes of **1c** and **1d** were found opposite to those of active derivatives in which their pending aromatic ring of THP **1c** and **1d** were located to the pyrimidine core of active compounds and their pyrimidine core of inactive compounds **1c** and **1d** were found to interact with the ribose pocket. The presence of a moderate group at the ortho position of phenyl such as NO~2~ and a large group at the para position of phenyl such as -N(CH~3~)~2~ was not favorable and prevents them to interact strongly with ribose pocket. The lack of interaction is due to the steric hindrance effect between these groups and the amino acid residues present in the ribose site that shift the aromatic ring to another binding site. This proves that the THP may act as potential TMK inhibitors. On the basis of the docking study, the substituent at position 4 of the phenyl group in the (*R*) form was more favorable for interacting with the residue ARG 95 because of its close proximity to the ribose interacting pocket compared with the corresponding *S* stereoisomer. However, further study is needed to determine which enantiomer form, *R* or *S*, would be responsible for MTB activity, hence confirming their mode of action. Figure 3The predicted docking poses of tetrahydropyrimidinone derivatives in the active site of MTB thymidylate kinase (PDB: 5NQ5). H-bond interactions are depicted as dotted green lines.Table 3Docking Results for Compounds **1a, b** and **2a, b** with the MTB Thymidylate Kinase Receptor (PDB: 5NQ5)EntryStereoisomer- CDocker E. (kcal/mol)H-Bond (Dist. Å, Interacting Atom)π Interaction1a*R*36.75ARG 74 (2.11, C=O ring)\
ARG 95 (2.40, CF~3~)\
ARG 107 (1.84, C=O ester)\
ASN 100 (3.02, NH ring)TYR 103 (π--π)\
ARG 95 (π--cation)*S*35.43ARG 74 (2.83, C=O ring)\
ASN 100 (2.61, NH ring)1b*R*31.92ARG 74 (2.87, C=O ring)\
ARG 95 (2.62, F)\
ARG 107 (2.16 C=O ester)ARG 95 (π--cation)*S*33.71ARG 74 (2.11, C=O ring)\
ARG 107 (1.87, C=O ester)\
ASN 100 (2.45, NH ring)2a*R*33.19ARG 74 (2.35, C=S ring)\
ARG 95 (2.44, CF~3~)\
ARG 107 (1.92 C=O ester)ARG 95 (π--cation)*S*35.43ARG 74 (2.12, C=O ring)\
ASN 100 (2.41, NH ring)2b*R*25.68ARG 74 (2.84, C=S ring)\
ARG 107 (2.29, 2.43, C=O ester)ARG 95 (π--cation)*S*29.90ARG 74 (2.07, C=S ring)\
ASN 100 (2.51, NH ring)

On the basis of the bioactivity, the leading compound **1a** was identified as a potential anti-TB agent. Further direction will be pursued to design more potent inhibitors through a structure-based drug design approach. [Figure 4](#F0004){ref-type="fig"} illustrates the design of a novel possible inhibitor. In terms of receptor specificity, the preliminary docking study revealed favorable interactions with substituted tetrahydropyrimidinone in R^1^ by the methyl and phenyl group and in R^2^ by --CF~3~, --F, --OH, --NH~2~, and --CO~2~H in both the para and meta positions. This new research direction will also help us to confirm the mechanism of action by which the molecules inhibit MTB. Figure 4Future development of anti-TB drug discovery research on novel substituted pyrimidinones.

ADME Prediction {#S0003-S2005}
---------------

The results of the ADME prediction by the SwissADME webserver are presented in [Table 4](#T0004){ref-type="table"}. All compounds obey the Lipinski rule of five conditions, except for compound **1d**, which has a single violation---specifically, the number of oxygen and nitrogen atoms is \>10. The number of rotatable bonds in each compound is \<7, which is preferred because it leads to a higher probability of being orally bioavailable. The cLog*P* and TPSA values ([Tables 1](#T0001){ref-type="table"} and [4](#T0004){ref-type="table"}, respectively) are also in the optimum range for most of the compounds. The predicted gastrointestinal absorption is high for all compounds, except for compound **1d**, which has a low predicted gastrointestinal absorption, possibly because of the high TPSA resulting from a large number of oxygen and nitrogen atoms in its structure. It can be concluded that the compounds, in general, have favorable properties that indicate oral bioavailability, with the exception of compound **1d**.Table 4The Predicted ADME Properties of 1,2,3,4-Tetrahydropyrimidinone (**1a--d**) and 1,2,3,4-Tetrahydropyrimidinethione (**2a--b**) CompoundsEntryRotatable BondsTPSAGI AbsorptionP-gp BindingBBB PermeantCYP InhibitionLipinski Violations1A22C92D61a467.43HighNoYesNoNoNo01b367.43HighNoNoNoNoNo01c470.67HighNoNoNoNoNo01d5159.07LowYesNoNoNoNo12a482.45HighNoNoNoYesNo02b382.45HighNoNoNoNoNo0

The predicted p-gp binding probability shows that none of the compounds, except for compound **1d**, are candidate substrates for p-gp; thus, the compounds are not expected to result in resistance via the efflux mechanism. The BBB permeability prediction indicates that the compounds are not permeable to the BBB; hence, they cannot enter the central nervous system. Only compound **1a** is predicted to be permeable to the BBB. Finally, the results of the CYP inhibition study show that most compounds do not inhibit any of the evaluated CYP isoforms; only compound **2a** is predicted to be a possible inhibitor of CYP2C9.

Conclusion {#S0004}
==========

In the present study, we designed several pyrimidinones and pyrimidinethiones as potential thymidylate kinase inhibitors, and the compounds were synthesized and evaluated for their anti-MTB activity. Our findings show that only pyrimidinone **1a** and pyrimidinethione **2a** demonstrate moderate anti-TB activity against MTB H37Rv strains. All compounds were found to be inactive against MTB strains resistant to the first-line antituberculosis drugs rifampicin and isoniazid, with the exception of pyrimidinethione **2a**, which showed weak inhibition. The presence of a trifluoromethyl group in the para position of the pendant aromatic ring is essential for retaining the activity of compounds **1a** and **2a**. Thymidylate kinase might be the molecular target responsible for the bioactivity of these compounds, although they did not exhibit any activity or demonstrated weak activity against rifampicin- and isoniazid-resistant MTB strains. The molecular docking studies reveal the importance of the size and the position of the substituent on the pendant aromatic ring of THP to interact favorably with the thymidylate kinase receptor. The trifluoromethyl group at 4-position of aryl of **1a** and **2a** was found to interact through hydrogen bonding with the ribose pocket receptor. The predicted binding modes of the inactive compounds **1c** and **1d** differ from those of **1a** and **2a**, explaining their lack of activity due to the steric hindrance effect of the group on the aromatic ring. The prediction and analysis of the ADME properties of the active compounds demonstrate favorable ADME properties; hence, compounds **1a** and **2a** can serve as potential lead compounds in the development of potential anti-TB drugs. However, further studies are needed to elucidate the mechanism of action by developing more potent inhibitors through an in silico structured-based design approach, as well as to identify which enantiomer form, *R* or *S*, is responsible for the bioactivity.
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[^1]: **Notes:** ^a^Yields calculated after being purified using the recrystallization method; ethanol was used as a solvent. ^b^cLog*P* of the title compounds was calculated using ChemDraw Professional 16.

[^2]: **Notes:** \*(ATCC: 25177). \*\*These isolates are resistant to the first-line antibiotics isoniazid (0.2 µg/mL) and rifampicin (1 µg/mL).

[^3]: **Abbreviations:** NA, not active (the concentration considered for screening was 0.2--128 µg/mL).
